Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
Primary objectives Part 1:
- To evaluate the safety and tolerability of COR-101 compared to placebo
Secondary objectives Part 1:
- To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized
patients with moderate to severe COVID-19
- To assess the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of
COR-101